| abstract |
A human antibody against human angiopoietin-like protein 4 is provided. A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human angiopoietin-like protein 4 (hANGPTL4) is provided. Human anti-hANGPTL4 antibodies are related to ANGPTL4 related diseases or disorders (including hyperlipidemia, hyperlipoproteinemia, and dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, etc.)) ) Is useful in treatment. Furthermore, anti-hANGPTL4 antibodies can be administered to a subject in need to prevent or treat a disease or disorder in which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases (such as atherosclerosis and coronary artery disease), acute pancreatitis, non-alcoholic steatohepatitis (NASH), diabetes, and obesity. [Selection figure] None |